NantHealth Stock Analysis, Valuation (NASDAQ:NH)

Add to My Stocks
$3.29 $0.17 (4.91%) NH stock closing price May 18, 2018 (Closing)
Watch Robo Advisor Video of NH Stock Analysis
NantHealth
Updated on : May 18, 2018
previous close
NH 3.3 (0%)
S&P 500 2713 (0%)
Closing Price On: May 18, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Information Systems
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2018-Q1
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-55.1%
Sector Average:
-12.2%
5 Quarter Net Profit
Net Margins
2018-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
196.7M
Debt/Equity Ratio:
 1.15
Compared to the industry
Cash Flow
Operating cash flow:
-$13.3M
Net Income:
-$22.2M
PROS      CONS
PS Valuation
Recent Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
NH PS :
3.9
Industry PS :
6.4
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-13.3%
Return on Equity:
-62.9%
Free Cash Flow Margin:
-61.8%
Double Tap To Exit Full Screen
0:00
/

NantHealth Stock Analysis

9 5 2

Investors can watch the Amigobulls NantHealth stock analysis video here. This video puts forward our latest analysis highlighting the pros and cons for NH stock.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

NantHealth Inc Stock Rating 1.8/5

Amigobulls NH stock analysis uses latest quarter 2018 Q1 financial data like NantHealth revenue growth, profit margins and cash flows. NantHealth valuation forms a crucial part of our stock analysis. Based on a company's historical fundamentals we arrive at NantHealth stock rating which is indicative of the company's financial performance.

Should you buy NH stock?

  • NH stock is trading at a favorable price to sales multiple of 3.9 as against the Medical-Information Systems industry average multiple of 6.4.

Should you sell NH stock?

  • NantHealth sales declined by -1.1% year on year in 2018 Q1.
  • NantHealth registered a negative operating margin of -55.1% (average) over the Trailing Twelve Months (TTM).
  • NantHealth posted an average Net loss of -168.8% in the last twelve months.
  • With a debt/equity ratio of  1.15, NantHealth is highly leveraged in comparison to Medical peers.
  • PE ratio is meaningless for NH stock as the company has losses.
  • The company has a negative Return on Invested Capital of -13.3%, which is a red flag.
  • NantHealth has a negative return on equity of -62.9%. This indicates that the firm is inefficient at generating profits.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -61.8%.

Comments on this video and NantHealth stock

Investors can use Amigobulls NantHealth stock analysis as a tool to arrive at accurate conclusions regarding financial health of the company and its valuation. The fundamentals of a company are vital to identify long-term investment opportunities.

NantHealth revenue growth and profit or net income are the main underlying forces which could detremine the direction of the share price. Investors could make use of NH technical analysis to check whether the fundamental story is reflected in the market sentiment.